Jiangsu Genscend Biopharmaceutical Co., Ltd

This early-stage study compares a new drug, GS101, to the approved treatment Dupixent® for atopic dermatitis (eczema). It involves 294 healthy adult volunteers in China to see how the body processes each drug, their safety, and any immune reactions. The goal is to check if GS101 …